(NASDAQ:ZENA) - Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease -
Related Questions
How will the $75 million upfront funding and potential $300 million total commitment affect Zenas' cash runway and dilution profile?
What is the market size and competitive landscape for obexelimab in IgG4‑Related Disease, and how does this partnership position Zenas against existing therapies?
What specific milestones and timelines are linked to the funding agreement, and how might meeting or missing them impact Zenas' valuation and risk profile?